keyword
MENU ▼
Read by QxMD icon Read
search

Relapsed b-cell lymphoma

keyword
https://www.readbyqxmd.com/read/30120708/car-t-cell-therapy-for-acute-lymphoblastic-leukemia-transforming-the-treatment-of-relapsed-and-refractory-disease
#1
REVIEW
Katherine C Pehlivan, Brynn B Duncan, Daniel W Lee
PURPOSE OF REVIEW: Genetically engineered T cells expressing a chimeric antigen receptor (CAR-T) targeting specific antigens present on acute lymphoblastic leukemia (ALL) blasts have generated promising results in children and adults with relapsed and refractory disease. We review the current evidence for CAR-T cell therapy in ALL, associated toxicities, and efforts to improve durable response to therapy. RECENT FINDINGS: CD19-directed CAR-T cells have recently been approved by the FDA for use in children and young adults with ALL and in adults with diffuse large B cell lymphoma (DLBCL) in the relapsed/refractory setting...
August 17, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/30115596/bendamustine-followed-by-obinutuzumab-and-venetoclax-in-chronic-lymphocytic-leukaemia-cll2-bag-primary-endpoint-analysis-of-a-multicentre-open-label-phase-2-trial
#2
Paula Cramer, Julia von Tresckow, Jasmin Bahlo, Sandra Robrecht, Petra Langerbeins, Othman Al-Sawaf, Anja Engelke, Anna-Maria Fink, Kirsten Fischer, Eugen Tausch, Till Seiler, Ludwig Fischer von Weikersthal, Holger Hebart, Karl-Anton Kreuzer, Sebastian Böttcher, Matthias Ritgen, Michael Kneba, Clemens-Martin Wendtner, Stephan Stilgenbauer, Barbara Eichhorst, Michael Hallek
BACKGROUND: Targeted agents such as the type II anti-CD20 antibody obinutuzumab and the B-cell lymphoma-2 antagonist venetoclax have shown impressive therapeutic activity in chronic lymphocytic leukaemia. The CLL2-BAG trial was initiated to investigate the combination of these two agents in patients with chronic lymphocytic leukaemia. METHODS: In this ongoing multicentre, open-label, investigator-initiated phase 2 trial, patients (aged ≥18 years) with chronic lymphocytic leukaemia requiring treatment according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria and an Eastern Cooperative Oncology Group performance status of 0-2 were enrolled at 16 sites in Germany...
August 13, 2018: Lancet Oncology
https://www.readbyqxmd.com/read/30112707/small-molecule-inhibitors-for-the-treatment-of-diffuse-large-b-cell-lymphoma
#3
REVIEW
Joanna Rhodes, Daniel J Landsburg
PURPOSE OF REVIEW: Diffuse large B cell lymphoma (DLBCL) remains the most common non-Hodgkin lymphoma (NHL) in developed countries. Up to 30-40% of patients experience either refractory or relapsed disease following receipt of front-line chemoimmunotherapy, and the majority of these patients will not be cured following receipt of subsequent therapy. RECENT FINDINGS: Small-molecule inhibitors (SMIs) are an attractive class of therapeutics for patients with chemorefractory DLBCL, and early-phase studies with these agents have typically demonstrated prolonged periods of disease control in responding patients without significant toxicity...
August 15, 2018: Current Hematologic Malignancy Reports
https://www.readbyqxmd.com/read/30112190/systematic-review-of-therapy-used-in-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-follicular-lymphoma
#4
REVIEW
Aaron Galaznik, Rachel Huelin, Michael Stokes, Yelan Guo, Meredith Hoog, Tarun Bhagnani, Jill Bell, Yaping Shou
To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we systematically reviewed literature in Medline/Embase for DLBCL/FL-related articles on real-world results published during January 2012-May 2016. Among 33 included articles, therapies included stem cell transplant (SCT) and chemotherapy, including experimental regimens. The highest overall survival rates were observed for SCT, long considered an optimal strategy following initial relapse...
July 2018: Future Science OA
https://www.readbyqxmd.com/read/30111607/intravascular-large-b-cell-lymphoma-a-chameleon-with-multiple-faces-and-many-masks
#5
Maurilio Ponzoni, Elias Campo, Shigeo Nakamura
Intravascular large B-cell lymphoma (IVLBCL) is a rare, clinically aggressive lymphoma entity characterized by an almost exclusive growth of large cells within the lumen of all sized blood vessels. The reasons for this peculiar localization of neoplastic cells are only partially understood. Clinically, in its classical variant, IVLBCL presents with many non-specific signs and symptoms such as fever of unknown origin and involvement of the central nervous system and skin. Cases, which show disease limited to the skin, following extensive staging work-up, are called cutaneous variants and show a better prognosis...
August 15, 2018: Blood
https://www.readbyqxmd.com/read/30104176/a-novel-combination-of-the-mtorc1-inhibitor-everolimus-and-the-immunomodulatory-drug-lenalidomide-produces-durable-responses-in-patients-with-heavily-pretreated-relapsed-lymphoma
#6
Leslie Padrnos, Brenda Ernst, Amylou C Dueck, Heidi E Kosiorek, Brenda F Ginos, Angela Toro, Patrick B Johnston, Thomas M Habermann, Jose F Leis, Joseph R Mikhael, Grzegorz S Nowakowski, Joseph Colgan, Luis Porrata, Stephen M Ansell, Thomas E Witzig, Craig Reeder
BACKGROUND: Treatment outcomes have improved in lymphoid malignancies but relapse remains inevitable for most patients. Everolimus and lenalidomide have shown clinical activity as single agents in patients with relapsed and refractory Hodgkin and non-Hodgkin lymphomas. PATIENTS AND METHODS: The present phase I/II trial for patients with relapsed and refractory lymphoid malignancy opened at Mayo Clinic from January 2011 to May 2013. The trial used a standard cohort 3 + 3 design to determine the maximum tolerated dose for the combination...
June 15, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/30102646/multiple-cavitary-lung-lesions-in-an-adolescent-case-report-of-a-rare-presentation-of-nodular-lymphocyte-predominant-hodgkin-lymphoma
#7
Moaaz Soliman, Fatima Neemuchwala, Amanda Sankar, Rama Jasty, Raja Rabah, Antonia P Popova, Erika A Newman
A 14-year-old male patient presented with a nonproductive cough, weight loss, fatigue, and malaise. A chest radiograph showed large bilateral cavitary lung lesions in both upper and lower lobes that failed to improve with antibiotics and anti-inflammatory medications. Infectious and rheumatologic work-ups were negative. Thoracoscopic lung biopsies were diagnostic for nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). The patient received combination chemotherapy and immunotherapy based on current treatment standards with an excellent clinical response...
August 10, 2018: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/30098915/visceral-leishmaniasis-in-hematopoietic-cell-transplantation-case-report-and-review-of-the-literature
#8
P Tatarelli, G Fornaro, V Del Bono, L A Nicolini, A M Raiola, F Gualandi, R Varaldo, T Di Muccio, M Gramiccia, L Gradoni, E Angelucci, C Viscoli, M Mikulska
Visceral leishmaniasis has been recognized as an opportunistic infection affecting people with cellular-immunity impairment, including hematopoietic cell transplantation (HCT) recipients. We describe the case of a young Italian man with Hodgkin lymphoma, who developed visceral leishmaniasis after multiple lines of chemotherapy and allogenic HCT. Literature review of visceral leishmaniasis in HCT recipients was also performed. Eleven patients (median age 50 years, 9 male) developed visceral leishmaniasis after allogenic (n = 9) and autologous (n = 2) HCT...
August 8, 2018: Journal of Infection and Chemotherapy: Official Journal of the Japan Society of Chemotherapy
https://www.readbyqxmd.com/read/30096458/bmi1-and-pten-are-key-determinants-of-breast-cancer-therapy-a-plausible-therapeutic-target-in-breast-cancer
#9
REVIEW
M Janaki Ramaiah, S Vaishnave
BMI-1 (B-lymphoma Mo-MLV insertion region 1) is a key protein partner in polycomb repressive complex 1 (PRC1) that helps in maintaining the integrity of the complex. It is also a key player in ubiquitination of histone H2A which affects gene expression pattern involved in various cellular processes such as cell proliferation, growth, DNA repair, apoptosis and senescence. In many cancers, Overexpression of BMI1correlates with advanced stages of disease, aggressive clinicopathological behavior, poor prognosis resistance to radiation and chemotherapy...
August 7, 2018: Gene
https://www.readbyqxmd.com/read/30094511/radiation-therapy-in-indolent-primary-cutaneous-b-cell-lymphoma-a-single-institute-experience
#10
Francesca De Felice, Lavinia Grapulin, Alessandra Pieroni, Francesca Salerno, Gianna Maria D'Elia, Alessandro Pulsoni, Daniela Musio, Vincenzo Tombolini
To report the clinical results after definitive radiotherapy (RT) for indolent primary cutaneous B cell lymphoma (pcBCL). The data concerning all patients treated for indolent pcBCL with RT with a curative intent between 1992 and 2012 were reviewed. All cases were (re)classified according to the World Health Organization (WHO) guidelines. A total of 42 patients with biopsy-proven primary cutaneous follicle center lymphoma (pcFCL) and primary cutaneous marginal zone lymphoma (pcMZL) were included. The median follow-up is 9...
August 10, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/30089630/anti-cd37-chimeric-antigen-receptor-t-cells-are-active-against-b-and-t-cell-lymphomas
#11
Irene Scarfò, Maria Ormhøj, Matthew J Frigault, Ana P Castano, Selena Lorrey, Amanda A Bouffard, Alexandria van Scoyk, Scott J Rodig, Alexandra J Shay, Jon C Aster, Frederic I Preffer, David M Weinstock, Marcela V Maus
Chimeric antigen receptor (CAR) T cells have emerged as a novel form of treatment for patients with B-cell malignancies. In particular, anti-CD19 CAR T-cell therapy has effected impressive clinical responses in B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). However, not all patients respond, and relapse with antigen loss has been observed in all patient subsets. Here, we report on the design and optimization of a novel CAR directed to the surface antigen CD37, which is expressed in B-cell non-Hodgkin Lymphomas, in chronic lymphocytic leukemia (CLL) and in some cases of cutaneous and peripheral T-cell lymphomas (CTCL and PTCL, respectively)...
August 8, 2018: Blood
https://www.readbyqxmd.com/read/30086544/r-ice-chemotherapy-with-or-without-autologous-transplantation-for-elderly-patients-with-relapsed-or-refractory-aggressive-b-cell-lymphomas
#12
Amin T Turki, Wolfgang Lamm, Tobias Liebregts, Ulrich Dührsen
No abstract text is available yet for this article.
August 8, 2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/30082475/phase-i-study-of-the-investigational-aurora-a-kinase-inhibitor-alisertib-plus-rituximab-or-rituximab-vincristine-in-relapsed-refractory-aggressive-b-cell-lymphoma
#13
Kevin R Kelly, Jonathan W Friedberg, Steven I Park, Kevin T McDonagh, John Hayslip, Daniel Persky, Jia Ruan, Soham Puvvada, Peter J Rosen, Swaminathan Padmanabhan Iyer, Alexandra Stefanovic, Steven H Bernstein, Steven Weitman, Anand B Karnad, Gregory Monohan, Ari VanderWalde, Raul Mena, Monika Schmelz, Catherine Spier, Susan Groshen, Karthik Venkatakrishnan, Xiaofei Zhou, Emily Sheldon-Waniga, E Jane Leonard, Daruka Mahadevan
PURPOSE: The aurora A kinase inhibitor alisertib demonstrated single-agent clinical activity and preclinical synergy with vincristine/rituximab in B-cell non-Hodgkin's lymphoma (B-NHL). This phase I study aimed to determine the safety and recommended phase II dose (RP2D) of alisertib in combination with rituximab ± vincristine in patients with relapsed/refractory aggressive B-NHL. EXPERIMENTAL DESIGN: Patients with relapsed/refractory, diffuse, large, or other aggressive B-NHL received oral alisertib 50 mg BID days 1-7, plus IV rituximab 375 mg/m2 on day 1, for up to eight 21-day cycles (MR)...
August 6, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/30078243/-clinical-and-prognostic-analysis-of-186-children-with-burkitt-s-lymphoma
#14
M Zhang, L Jin, J Yang, Y L Duan, S Huang, C J Zhou, Y H Zhang
Objective: To analyze the clinical features and prognostic factors of childhood Burkitt's lymphoma and to summarize the therapeutic effect of the mature B-cell lymphoma regimen of Beijing Children's Hospital. Methods: It was a retrospective study. From January 2007 to December 2015, 186 patients below 18 years of age with newly diagnosed, untreated Burkitt's lymphoma were enrolled. Three cases were eliminated because of the abandonment of the treatment and 183 cases were stratified and treated according to the mature B-cell lymphoma regimen of Beijing Children's Hospital, groups were as follows: A, n= 1; B, n= 59; C, n= 123 and 97 patients in group C received combined rituximab therapy during the treatment...
August 2, 2018: Zhonghua Er Ke za Zhi. Chinese Journal of Pediatrics
https://www.readbyqxmd.com/read/30071836/case-report-persistently-seronegative-neuroborreliosis-in-an-immunocompromised-patient
#15
A Wagemakers, M C Visser, B de Wever, J W Hovius, N W C J van de Donk, E J Hendriks, L Peferoen, F F Muller, C W Ang
BACKGROUND: Infection with Borrelia burgdorferi sensu lato complex (B. b. sl) spirochetes can cause Lyme borreliosis, manifesting as localized infection (e.g. erythema migrans) or disseminated disease (e.g. Lyme neuroborreliosis). Generally, patients with disseminated Lyme borreliosis will produce an antibody response several weeks post-infection. So far, no case of neuroborreliosis has been described with persistently negative serology one month after infection. CASE PRESENTATION: We present a patient with a history of Mantle cell lymphoma and treatment with R-CHOP (rituximab, doxorubicine, vincristine, cyclofosfamide, prednisone), with a meningo-encephalitis, who was treated for a suspected lymphoma relapse...
August 2, 2018: BMC Infectious Diseases
https://www.readbyqxmd.com/read/30060083/venetoclax-bendamustine-and-rituximab-in-patients-with-relapsed-or-refractory-nhl-a-phase-1b-dose-finding-study
#16
S de Vos, L J Swinnen, D Wang, E Reid, N Fowler, J Cordero, M Dunbar, S H Enschede, C Nolan, A M Petrich, J A Ross, A H Salem, M Verdugo, S Agarwal, L Zhou, M Kozloff, L J Nastoupil, C R Flowers
Background: Venetoclax is a selective, potent inhibitor of the anti-apoptotic BCL-2 protein approved for treatment of chronic lymphocytic leukemia. We conducted a dose-finding study of venetoclax in combination with bendamustine-rituximab (BR) in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). Patients and methods: BR was given for 6 cycles at standard doses. Intermittent and continuous oral venetoclax administration was explored at 50mg-1200mg daily doses...
July 28, 2018: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/30049735/pro-b-advani-r-brice-p-et-al-five-year-results-of-brentuximab-vedotin-in-patients-with-relapsed-or-refractory-systemic-anaplastic-large-cell-lymphoma-blood-2017-130-25-2709-2717
#17
https://www.readbyqxmd.com/read/30047174/selective-contrast-enhanced-computed-tomography-is-appropriate-in-diffuse-large-b-cell-lymphoma-therapy-response-assessment
#18
Katharina Kriegsmann, Maurizio Wack, Mark Kriegsmann, Martin Cremer, Thomas Bruckner, Anthony D Ho, Patrick Wuchter, Mathias Witzens-Harig
OBJECTIVE: Although not the gold standard, contrast-enhanced CT of neck, thorax, and abdomen/pelvis is routinely performed in diagnosis and response assessment of DLBCL. PD during first line treatment is a relatively rare event. The question arises if the imaging of initially involved regions only might be sufficient for response evaluation. METHOD: We retrospectively analyzed the data of 167 DLBCL patients who had an extensive contrast-enhanced CT scan at first diagnosis...
July 26, 2018: European Journal of Haematology
https://www.readbyqxmd.com/read/30045683/cerebral-aspergillosis-in-a-patient-on-ibrutinib-therapy-a-predisposition-not-to-overlook
#19
Muhammad Salman Faisal, Hira Shaikh, Ahmed Khattab, Mary Albrethsen, Salman Fazal
Ibrutinib has revolutionized the treatment of B-cell malignancies since its approval for chronic lymphocytic leukemia. It is also used in mantle cell lymphoma, diffuse large B-cell lymphoma, Waldenstrom's macroglobulinemia, among others. It is a Bruton's tyrosine kinase inhibitor that acts on B-cell receptor signaling pathway and predisposes to various infections due to its effects on neutrophils, monocytes and T cells. We present a case of cerebral invasive aspergillosis in a patient being treated with ibrutinib for relapsed chronic lymphocytic leukemia...
July 25, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/30045337/monoclonal-gammopathies-regardless-of-subtypes-are-associated-with-poor-prognosis-of-diffuse-large-b-cell-lymphoma-a-strobe-compliant-article
#20
Yian Zhang, Zheng Wei, Jing Li, Rupan Gao, Peng Liu
Monoclonal gammopathy (MG), a positive result of serum immunofixation electrophoresis (SIFE), has been reported in cases of diffuse large B-cell lymphoma (DLBCL). We performed this study to further investigate the prognostic value of MG in DLBCL.We retrospectively reviewed patients diagnosed with DLBCL between January 2007 and December 2014, and identified 37 patients with MG. The clinical characteristics of these patients were then reviewed. A 1:2 case-control analysis was conducted on 74 matched controls, who were patients with DLBCL and without MG...
July 2018: Medicine (Baltimore)
keyword
keyword
171524
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"